Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes

T. Vahdat, Linda; Donnall Thomas, E.; Li, R.; Jassem, Jacek; Gómez, Henry; Chung, HC; Peck, R.; Mukhopadhyay, P.; Klimovsky, Judith; Roché, Henri

doi:10.1200/jco.2007.25.18_suppl.1006

Public

Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes

Shared by NobleBlocks on Jun 20, 2007 • 12:00 AM UTC

Authors:

Linda T. Vahdat

E. Donnall Thomas

R. Li

Abstract

1006 Background: Patients with MBC who have progressed after anthracyclines and taxanes have limited treatment options. Ixabepilone, a novel epothilone B analog, is active in resistant breast cancer. Methods: In this large multinational phase III trial, patients with MBC who were anthracycline pretr...

Subject

Ixabepilone

Capecitabine

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!